Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit
December 6, 2018
Houston, TX – December 6, 2018 – Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present a corporate overview at the upcoming Tumor Targeted Lymphocytes Summit on Wednesday, December 12, 2018.
Title: A Novel Therapy That Targets Multiple Tumor Antigens Using Non-Genetically Modified T Cells Can Drive Powerful Anti-Tumor Response
Date: Wednesday, December 12, 2018
Time: 12:30pm EST
***Time of Presentation has been changed to 12:15pm EST***
Location: Hilton Boston Back Bay, Boston, MA[/vc_column_text][vc_empty_space height=”4px”][vc_column_text][mrkrdisclaimertrout]